Geronikaki A
    
    
    Int J Mol Sci. 2025; 25(24.
  
  
    PMID: 39769186
    
          PMC: 11678085.
    
          DOI: 10.3390/ijms252413422.
      
 
                                  
  
    Corboz M, Nguyen T, Stautberg A, Cipolla D, Perkins W, Chapman R
    
    
    J Aerosol Med Pulm Drug Deliv. 2024; 37(5):241-283.
  
  
    PMID: 39388691
    
          PMC: 11502635.
    
          DOI: 10.1089/jamp.2024.0016.
      
 
                                  
  
    Fang X, Chen J, Hu Z, Shu L, Wang J, Dai M
    
    
    J Am Heart Assoc. 2024; 13(19):e035868.
  
  
    PMID: 39344593
    
          PMC: 11681457.
    
          DOI: 10.1161/JAHA.124.035868.
      
 
                                  
  
    Abouzaid A, Ali K, Jatoi S, Ahmed M, Ahmad G, Nazim A
    
    
    Ann Noninvasive Electrocardiol. 2024; 29(5):e70010.
  
  
    PMID: 39205610
    
          PMC: 11358588.
    
          DOI: 10.1111/anec.70010.
      
 
                                  
  
    Davies M, Hart J
    
    
    Front Cardiovasc Med. 2024; 10:1298686.
  
  
    PMID: 38179509
    
          PMC: 10764581.
    
          DOI: 10.3389/fcvm.2023.1298686.
      
 
                              
              
                              
                                      
  Angiotensin-Converting Enzyme 2 (ACE2) Signaling in Pulmonary Arterial Hypertension: Underpinning Mechanisms and Potential Targeting Strategies.
  
    Papavassiliou K, Gogou V, Papavassiliou A
    
    
    Int J Mol Sci. 2023; 24(24).
  
  
    PMID: 38139269
    
          PMC: 10744156.
    
          DOI: 10.3390/ijms242417441.
      
 
                                          
                                                          
  Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy.
  
    Miles K, Critser P, Evers P, Cash M, Magness M, Geers E
    
    
    Pulm Circ. 2023; 13(3):e12264.
  
  
    PMID: 37427091
    
          PMC: 10323166.
    
          DOI: 10.1002/pul2.12264.
      
 
                                          
                                                          
  Alleviating experimental pulmonary hypertension  co-delivering FoxO1 stimulus and apoptosis activator to hyperproliferating pulmonary arteries.
  
    Li B, Teng C, Yu H, Jiang X, Xing X, Jiang Q
    
    
    Acta Pharm Sin B. 2023; 13(6):2369-2382.
  
  
    PMID: 37425053
    
          PMC: 10326245.
    
          DOI: 10.1016/j.apsb.2022.12.002.
      
 
                                          
                                                          
  Pulmonary Hypertension in Left Heart Diseases: Pathophysiology, Hemodynamic Assessment and Therapeutic Management.
  
    Ltaief Z, Yerly P, Liaudet L
    
    
    Int J Mol Sci. 2023; 24(12).
  
  
    PMID: 37373119
    
          PMC: 10298585.
    
          DOI: 10.3390/ijms24129971.
      
 
                                          
                                                          
  The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure.
  
    Xu Y, Yang B, Hui J, Zhang C, Bian X, Tao M
    
    
    Front Cardiovasc Med. 2023; 10:1125014.
  
  
    PMID: 37273885
    
          PMC: 10233066.
    
          DOI: 10.3389/fcvm.2023.1125014.
      
 
                                          
                                                          
  New Drugs and Therapies in Pulmonary Arterial Hypertension.
  
    Shah A, Beckmann T, Vorla M, Kalra D
    
    
    Int J Mol Sci. 2023; 24(6).
  
  
    PMID: 36982922
    
          PMC: 10058689.
    
          DOI: 10.3390/ijms24065850.
      
 
                                          
                                                          
  The emerging role of the piRNA/PIWI complex in respiratory tract diseases.
  
    Yao Y, Li Y, Zhu X, Zhao C, Yang L, Huang X
    
    
    Respir Res. 2023; 24(1):76.
  
  
    PMID: 36915129
    
          PMC: 10010017.
    
          DOI: 10.1186/s12931-023-02367-9.
      
 
                                          
                                                          
  Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure.
  
    Joshi S, Atabay E, Liu J, Ding Y, Briscoe S, Alexander M
    
    
    Front Cardiovasc Med. 2023; 10:1064290.
  
  
    PMID: 36910526
    
          PMC: 9996114.
    
          DOI: 10.3389/fcvm.2023.1064290.
      
 
                                          
                                                          
  Effects and related mechanism of alpha-adrenergic receptor inhibitor phentolamine in a rabbit model of acute pulmonary embolism combined with shock.
  
    Wang Y, Qiu L, Yu D, Yu Y, Hu L, Gu Y
    
    
    Eur J Med Res. 2022; 27(1):238.
  
  
    PMID: 36348473
    
          PMC: 9641939.
    
          DOI: 10.1186/s40001-022-00842-5.
      
 
                                          
                                                          
  Current status of pulmonary artery denervation.
  
    Davies M, Miserlis D, Hart J
    
    
    Front Cardiovasc Med. 2022; 9:972256.
  
  
    PMID: 36262207
    
          PMC: 9573987.
    
          DOI: 10.3389/fcvm.2022.972256.
      
 
                                          
                                                          
  Symptom phenotypes in pulmonary arterial hypertension: The PAH "symptome".
  
    Matura L, Fargo J, Boyle K, Fritz J, Smith K, Mazurek J
    
    
    Pulm Circ. 2022; 12(3):e12135.
  
  
    PMID: 36186717
    
          PMC: 9511227.
    
          DOI: 10.1002/pul2.12135.
      
 
                                          
                                                          
  An explorative metabolomic analysis of the endothelium in pulmonary hypertension.
  
    Carlsen J, Henriksen H, Marin de Mas I, Johansson P
    
    
    Sci Rep. 2022; 12(1):13284.
  
  
    PMID: 35918401
    
          PMC: 9345936.
    
          DOI: 10.1038/s41598-022-17374-x.
      
 
                                          
                                                          
  Proteomic and Metabolomic Analyses of Right Ventricular Failure due to Pulmonary Arterial Hypertension.
  
    Qin X, Lei C, Yan L, Sun H, Liu X, Guo Z
    
    
    Front Mol Biosci. 2022; 9:834179.
  
  
    PMID: 35865003
    
          PMC: 9294162.
    
          DOI: 10.3389/fmolb.2022.834179.
      
 
                                          
                                                          
  AMPK and the Challenge of Treating Hypoxic Pulmonary Hypertension.
  
    Flores K, Siques P, Brito J, Arribas S
    
    
    Int J Mol Sci. 2022; 23(11).
  
  
    PMID: 35682884
    
          PMC: 9181235.
    
          DOI: 10.3390/ijms23116205.
      
 
                                          
                                                          
  Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model.
  
    Lu M, Chen L, Gairhe S, Mazer A, Anderson S, Nelson J
    
    
    Am J Physiol Lung Cell Mol Physiol. 2022; 322(3):L315-L332.
  
  
    PMID: 35043674
    
          PMC: 8858673.
    
          DOI: 10.1152/ajplung.00238.2021.